📢 New Research Alert: Does Baseline Cardiovascular Risk Influence the Benefit of LDL-C Lowering in Primary Prevention? A new systematic review and meta-analysis challenges conventional thinking about LDL-C lowering in primary prevention, demonstrating that the relative benefit of pharmacologic LDL-C reduction may actually be greater in lower-risk populations. Key findings: 🔹 Analysis of 17 randomized trials involving more than 105,000 participants found that the relative risk reduction (RRR) associated with each 1 mmol/L reduction in LDL-C was substantially greater in lower-risk populations than in higher-risk populations. 🔹 At an annual cardiovascular event rate of 1%, a 1 mmol/L LDL-C reduction was associated with an estimated 36% reduction in major adverse cardiovascular events, compared with 13% at a 3% annual event rate. 🔹 Higher-risk populations required substantially larger absolute LDL-C reductions to achieve comparable relative benefits. 🔹 The findings support consideration of earlier LDL-C lowering strategies before cardiovascular risk becomes established. These results add to the growing body of evidence that cumulative LDL-C exposure matters—and that earlier intervention may yield meaningful long-term cardiovascular benefits. 📖 Read the article: sciencedirect.com/science/ar… #PreventiveCardiology #LDLCholesterol #PrimaryPrevention #ASCVD #LipidManagement #CardiovascularPrevention #CardiologyResearch #Cholesterol #HeartHealth #EvidenceBasedMedicine